Andreas S. Barth

Assistant Professor

Johns Hopkins University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Background Pathogenic variants in the desmin gene ( DES ) are implicated in diverse cardiomyopathy and skeletal myopathy phentoypes with high rates of major adverse cardiac events (MACE). Although pediatric cases have been reported, the genetic profile, clinical features and outcomes in affected children remain poorly defined. This study aimed to comprehensively characterize these aspects in the pediatric population. Methods We conducted a systematic review and individual patient data meta-analysis of Medline (PubMed) and Embase, including patients with pathogenic or likely pathogenic DES variant(s) diagnosed before age 21. MACE were defined as cardiac conduction disease (CCD) requiring device implantation, sustained ventricular arrhythmias (VA), and heart failure (HF) events. Results Fifty-one pediatric patients were included (58.8% male; 64.7% probands; median age at first evaluation: 14.0 years [IQR 11.0–17.0], median follow-up: 5.0 years [1.0–11.5]). Among probands, 60.6% (20/33) had a heterozygous variant (20 non-frameshift/non-truncating and 2 frameshift/truncating), while the remaining 11 (33.3%) harbored biallelic genotypes (homozygous (n=8), compound heterozygous (n=3)). At presentation, 54.9% (28/51) patients had cardiomyopathy and 54.9% had skeletal myopathy. CCD occurred in 39.2% (median age: 19.0 years), sustained VA in 21.6% (median age: 18.0 years), and HF events in 37.3% (median age: 19.0 years). In total, 64.7% experienced MACE (median age: 17.0 years [13.0–19.0]), and 19.6% died during follow-up (median age: 23.5 years [14.8–28.0]). Rates of cardiomyopathy diagnosis, CCD, VA and HF events as well as composite MACE were similar between those with a heterozygous and biallelic variants (p>0.05 for all), but the latter group had nearly twice higher rate of skeletal myopathy (43.6% vs 83.3%, p=0.016). Conclusion Pediatric DES- associated disease is characterized by heterogeneous cardiomyopathy phenotypes and substantially high MACE burden. Probands were more likely than genotype-positive relatives to develop CCD and HF events, while sustained VA rates were similar and substantial in both groups. Cardiomyopathy rates and outcomes were comparable between patients with heterozygous and biallelic variants. WHAT IS KNOWN? Desmin ( DES )-associated cardiomyopathy is a rare genetic disorder characterized by variable cardiac and skeletal muscle involvement, typically presenting in adulthood with conduction system disease, ventricular arrhythmias, or heart failure. While case reports suggest that pediatric onset is possible, the clinical features, genetic landscape, and outcomes in children remain poorly characterized. WHAT THE STUDY ADDS In pediatric patients with DES variants, cardiac phenotype expression can commence in early childhood and rapidly progresses with age, with two-thirds of patients experiencing major adverse cardiac events by young adulthood, highlighting the critical need for initiation of comprehensive cardiac evaluation in early childhood in patients with DES variants. Cardiac conduction disease and heart failure were the most common events in pediatric DES patients, especially in probands, though arrhythmic risk was present, and substantial, both in probands and relatives. Multisystem involvement, including skeletal muscle symptoms, was common in pediatric DES patients, particularly those with biallelic variants, underscoring the importance of early genetic testing and longitudinal, multidisciplinary surveillance in at-risk children, regardless of family history.

Year:

2025

Background Genetic diagnosis has become increasingly important to guide clinical decision making for patients with dilated cardiomyopathy (DCM). Disease-causing (P/LP) missense variants in the gene RBM20 cause a highly penetrant arrhythmogenic dilated cardiomyopathy (DCM), but the role of truncating RBM20 variants ( RBM20tvs ) is unclear. Objective Assess the contribution of RBM20tvs to DCM. Methods We assembled an international cohort of DCM patients with RBM20 variants and used data from the genome-first UK Biobank (UKB) to assess the etiologic fraction, natural history and penetrance of RBM20tvs . Results The etiologic fraction of RBM20tvs in arrhythmogenic DCM was modest (0.53[0.32,0.67], p=7.5×10 -5 ). RBM20tv DCM patients presented to referral centers later in life than RBM20 P/LP DCM patients (53±10 vs. 34±18 years, p=4×10 -3 ), and were less likely to have a family history of sudden cardiac arrest (20% vs. 65%, p= 0.046) or cardiomyopathy (20% vs. 78% p=5.4×10 -3 ). There was no significant difference in age- and sex-adjusted incident major heart failure or arrhythmia events between RBM20tv and RBM20 P/LP DCM patients, though sex-adjusted lifetime hazard was reduced in RBM20tv DCM (HR 0.15[0.03,0.66],p=0.009). In UKB, lifetime incidence of cardiomyopathy, heart failure, or major ventricular arrhythmia diagnosis was lower in participants with RBM20tvs than in those with TTNtvs (HR 0.55 [0.36,0.84], p=5.9×10 -3 ). Conclusions RBM20tvs contribute to arrhythmogenic DCM phenotypes, but confer milder disease severity alone than RBM20 P/LP variants, and reduced lifetime disease penetrance compared to TTNtvs . Their potential for additive interactions with other damaging variants should be considered in DCM patients and families.

Year:

2025

Background Pathogenic/likely pathogenic (P/LP) desmin ( DES ) variants cause heterogeneous cardiomyopathy and/or skeletal myopathy phenotypes. Limited data suggest a high incidence of major adverse cardiac events (MACE), including cardiac conduction disease (CCD), sustained ventricular arrhythmias (VA), and heart failure (HF) events (HF hospitalization, LVAD/cardiac transplant, HF-related death), in patients with P/LP DES variants. However, pleiotropic presentation and small cohort sizes have limited clinical phenotype and outcome characterization. Objectives We aimed to describe the natural history, phenotype spectrum, familial penetrance and outcomes in patients with P/LP DES variants through a systematic review and individual patient data meta-analysis using published reports. Methods We searched Medline (PubMed) and Embase for studies that evaluated cardiac phenotypes in patients with P/LP DES variants. Cardiomyopathy diagnosis or occurrence of MACE were considered evidence of cardiac involvement/penetrance. Lifetime event-free survival from CCD, sustained VA, HF events, and composite MACE was assessed. Results Out of 4,212 screened publications, 71 met the inclusion criteria. A total of 230 patients were included (52.6% male, 52.2% probands, median age: 31 years [22.0; 42.8] at first evaluation, median follow-up: 3 years [0; 11.0]). Overall, 124 (53.9%) patients were diagnosed with cardiomyopathy, predominantly dilated cardiomyopathy (14.8%), followed by restrictive cardiomyopathy (13.5%), whereas other forms were less common: arrhythmogenic cardiomyopathy (7.0%), hypertrophic cardiomyopathy (6.1%), arrhythmogenic right ventricular cardiomyopathy (5.2%), and other forms (7.4%). Overall, 132 (57.4%) patients developed MACE, with 96 [41.7%] having CCD, 36 [15.7%] sustained VA, and 43 [18.7%] HF events. Familial penetrance of cardiac disease was 63.6% among relatives with P/LP DES variants. Male sex was associated with increased risk of sustained VA (HR 2.28, p=0.02) and HF events (HR 2.45, p=0.008). Conclusions DES cardiomyopathy exhibits heterogeneous phenotypes and distinct natural history, characterized by high familial penetrance and substantial MACE burden. Male patients face higher risk of sustained VA events.

Year:

2024

Genetic testing has become standard of care for patients with long QT syndrome (LQTS), providing diagnostic, prognostic, and therapeutic information for both probands and their family members. However, up to a quarter of patients with LQTS do not have identifiable Mendelian pathogenic variants in the currently known LQTS-associated genes. This absence of genetic confirmation, intriguingly, does not lessen the severity of LQTS, with the prognosis in these gene-elusive patients with unequivocal LQTS mirroring genotype-positive patients in the limited data available. Such a conundrum instigates an exploration into the causes of corrected QT interval (QTc) prolongation in these cases, unveiling a broad spectrum of potential scenarios and mechanisms. These include multiple environmental influences on QTc prolongation, exercise-induced repolarization abnormalities, and the profound implications of the constantly evolving nature of genetic testing and variant interpretation. In addition, the rapid advances in genetics have the potential to uncover new causal genes, and polygenic risk factors may aid in the diagnosis of high-risk patients. Navigating this multifaceted landscape requires a systematic approach and expert knowledge, integrating the dynamic nature of genetics and patient-specific influences for accurate diagnosis, management, and counseling of patients. The role of a subspecialized expert cardiogenetic clinic is paramount in evaluation to navigate this complexity. Amid these intricate aspects, this review outlines potential causes of gene-elusive LQTS. It also provides an outline for the evaluation of patients with negative and inconclusive genetic test results and underscores the need for ongoing adaptation and reassessment in our understanding of LQTS, as the complexities of gene-elusive LQTS are increasingly deciphered.

Year:

2024

Background Heart failure (HF) has been increasing in prevalence, and a need exists for biomarkers with improved predictive and prognostic ability. GDF‐15 (growth differentiation factor‐15) is a novel biomarker associated with HF mortality, but no serial studies of GDF‐15 have been conducted. This study aimed to investigate the association between GDF‐15 levels over time and the occurrence of ventricular arrhythmias, HF hospitalizations, and all‐cause mortality. Methods and Results We used a retrospective case–control design to analyze 148 patients with ischemic and nonischemic cardiomyopathies and primary prevention implantable cardioverter‐defibrillator (ICD) from the PROSe‐ICD (Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention) cohort. Patients had blood drawn every 6 months and after each appropriate ICD therapy and were followed for a median follow‐up of 4.6 years, between 2005 to 2019. We compared serum GDF‐15 levels within ±90 days of an event among those with a ventricular tachycardia/fibrillation event requiring ICD therapies and those hospitalized for decompensated HF. A comparator/control group comprised patients with GDF‐15 levels available during 2‐year follow‐up periods without events. Median follow‐up was 4.6 years in the 148 patients studied (mean age 58±12, 27% women). The HF cohort had greater median GDF‐15 values within 90 days (1797 pg/mL) and 30 days (2039 pg/mL) compared with the control group (1062 pg/mL, both P <0.0001). No difference was found between the ventricular tachycardia/fibrillation subgroup within 90 days (1173 pg/mL, P =0.60) or 30 days (1173 pg/mL, P =0.78) and the control group. GDF‐15 was also significantly predictive of mortality (hazard ratio, 3.17 [95% CI, 2.33–4.30]). Conclusions GDF‐15 levels are associated with HF hospitalization and mortality but not ventricular arrhythmic events.

Year:

2023

Collaborators (23)

Sharlene Day

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Anjali T. Owens

Assistant Professor, Clinician-Educator

University of Pennsylvania Perelman School of Medicine

UNITED STATES
View details

Eric Smith

University of Michigan

UNITED STATES
View details

Benjamin Meder

W3 Professor

University Hospital Heidelberg

GERMANY
View details

Bruna Filipa Gomes Botelho Quintas

Fachärztin

University Hospital Heidelberg

GERMANY
View details

Daniel Judge

Professor

Medical University of South Carolina

UNITED STATES
View details

Julia Cadrin-Tourigny

Clinical Assistant Professor

Université de Montréal

CANADA
View details

Stefan Zimmerman

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Adam Helms

Assistant Professor

University of Michigan

UNITED STATES
View details

Vasanth Vedantham

Professor

University of California, San Francisco

UNITED STATES
View details

Andrew D Krahn

Professor

The University of British Columbia

CANADA
View details

Doris Leung

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Diane Fatkin

Victor Chang Cardiac Research Institute

AUSTRALIA
View details

Gianfranco Sinagra

University of Trieste

ITALY
View details

Hugh Calkins

Johns Hopkins University School of Medicine

UNITED STATES
View details

Cynthia James

Associate Professor

Johns Hopkins University

UNITED STATES
View details

Nosheen Reza

University of Pennsylvania

UNITED STATES
View details

Euan A. Ashley

Professor

Stanford University School of Medicine

UNITED STATES
View details

Ardan M. Saguner

-

SWITZERLAND
View details

Kristen Medo

Research Services Professional

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Luisa Mestroni

Professor of Medicine

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Chad Mao

Children's Healthcare of Atlanta

UNITED STATES
View details

Perry Elliott

University College London

UNITED KINGDOM
View details